References
ABDELWAHAB, S. I., MOHAN, S., MOHAMED ELHASSAN, M., AL-MEKHLAFI, N., MARIOD, A. A., ABDUL, A. B., ABDULLA, M. A. & ALKHARFY, K. M. 2011. Antiapoptotic and antioxidant properties of Orthosiphon stamineus benth (Cat's Whiskers): intervention in the Bcl-2-mediated apoptotic pathway. Evidence-Based Complementary and Alternative Medicine, 2011.
Abdul Majid, AMS ; Majid, ASA. (2018). Cat Whiskers Herb, the herb that is Purrr..fect for your Health. Australian Herbal Insight, 1(1), pages 1–3.
ADNYANA, I. K., SETIAWAN, F. & INSANU, M. 2013. From ethnopharmacology to clinical study of Orthosiphon stamineus Benth. studies, 1.
AHAMED, M. B. K., AISHA, A. F., NASSAR, Z. D., SIDDIQUI, J. M., ISMAIL, Z., OMARI, S., PARISH, C. & MAJID, A. A. 2012. Cat's whiskers tea (Orthosiphon stamineus) extract inhibits growth of colon tumor in nude mice and angiogenesis in endothelial cells via suppressing VEGFR phosphorylation. Nutrition and Cancer, 64, 89-99.
ALMATAR, M., EKAL, H. & RAHMAT, Z. 2014. A glance on medical applications of Orthosiphon stamineus and some of its oxidative compounds. Int J Pharm Sci Rev Res, 24, 83-88.
BALA, A., KAR, B., KARMAKAR, I., KUMAR, R. S. & HALDAR, P. K. 2012. Antioxidant activity of Cat's whiskers flavonoid on some reactive oxygen and nitrogen species generating inflammatory cells is mediated by scavenging of free radicals. Chinese journal of natural medicines, 10, 321-327.
BALLESTRI, S., ZONA, S., TARGHER, G., ROMAGNOLI, D., BALDELLI, E., NASCIMBENI, F., ROVERATO, A., GUARALDI, G. & LONARDO, A. 2016. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. Journal of gastroenterology and hepatology, 31, 936-944.
BAR-OR, D. & BAR-OR, R. 2013. Measurement and uses of oxidative status. Google Patents.
BENEDICT, M. & ZHANG, X. 2017. Non-alcoholic fatty liver disease: An expanded review. World journal of hepatology, 9, 715.
CHOI, H., DE VERA, M. & KRISHNAN, E. 2008. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology, 47, 1567-1570.
ECKEL, R. H., GRUNDY, S. M. & ZIMMET, P. Z. 2005. The metabolic syndrome. The lancet, 365, 1415-1428.
EHRMANN, D. A., LILJENQUIST, D. R., KASZA, K., AZZIZ, R., LEGRO, R. S., GHAZZI, M. N. & GROUP, P. T. S. 2006. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 91, 48-53.
FAGOT-CAMPAGNA, A., PETTITT, D. J., ENGELGAU, M. M., BURROWS, N. R., GEISS, L. S., VALDEZ, R., BECKLES, G. L., SAADDINE, J., GREGG, E. W. & WILLIAMSON, D. F. 2000. Type 2 diabetes among North adolescents: An epidemiologic health perspective. The Journal of pediatrics, 136, 664-672.
GAGGINI, M., MORELLI, M., BUZZIGOLI, E., DEFRONZO, R. A., BUGIANESI, E. & GASTALDELLI, A. 2013. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients, 5, 1544-1560.
GRUNDY, S. M., CLEEMAN, J. I., DANIELS, S. R., DONATO, K. A., ECKEL, R. H., FRANKLIN, B. A., GORDON, D. J., KRAUSS, R. M., SAVAGE, P. J. & SMITH JR, S. C. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation, 112, 2735-2752.
HENCH, P. S. 1936. The diagnosis of gout and gouty arthritis. The Journal of Laboratory and Clinical Medicine,22, 48-55.
ISHIZAKA, N., ISHIZAKA, Y., TODA, E.-I., NAGAI, R. & YAMAKADO, M. 2005. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arteriosclerosis Thrombosis and Vascular Biology, 25, 1038-1044.
JEONG, I. G., KANG, T., BANG, J. K., PARK, J., KIM, W., HWANG, S. S., KIM, H. K. & PARK, H. K. 2011. Association between metabolic syndrome and the presence of kidney stones in a screened population. American Journal of Kidney Diseases, 58, 383-388.
JOHNSON, R. J., SEGAL, M. S., SAUTIN, Y., NAKAGAWA, T., FEIG, D. I., KANG, D.-H., GERSCH, M. S., BENNER, S. & SÁNCHEZ-LOZADA, L. G. 2007. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease–. The American journal of clinical nutrition, 86, 899-906.
KELISHADI, R., ALIKHANI, S., DELAVARI, A., ALAEDINI, F., SAFAIE, A. & HOJATZADEH, E. 2008. Obesity and associated lifestyle behaviours in Iran: findings from the first national non-communicable disease risk factor surveillance survey. Public health nutrition, 11, 246-251.
KUPELIAN, V., MCVARY, K. T., KAPLAN, S. A., HALL, S. A., LINK, C. L., AIYER, L. P., MOLLON, P., TAMIMI, N., ROSEN, R. C. & MCKINLAY, J. B. 2009. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. The Journal of urology, 182, 616-625.
LIVER, E. A. F. T. S. O. T. & DIABETES, E. A. F. T. S. O. 2016. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obesity facts, 9, 65-90.
LONARDO, A., BALLESTRI, S., MARCHESINI, G., ANGULO, P. & LORIA, P. 2015. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease, 47, 181-190.
LOVE-OSBORNE, K. A., NADEAU, K. J., SHEEDER, J., FENTON, L. Z. & ZEITLER, P. 2008. Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. Journal of Adolescent Health, 42, 543-548.
MCFARLANE, S. I. & SOWERS, J. R. 2003. Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. The Journal of Clinical Endocrinology & Metabolism, 88, 516-523.
MISRA, A. & KHURANA, L. 2008. Obesity and the metabolic syndrome in developing countries. The Journal of Clinical Endocrinology & Metabolism, 93, s9-s30.
NGUYEN, M. T. T., AWALE, S., TEZUKA, Y., LE TRAN, Q., WATANABE, H. & KADOTA, S. 2004. Xanthine oxidase inhibitory activity of Vietnamese medicinal plants. Biological and Pharmaceutical Bulletin, 27,1414-1421.
PITTENGER, G. L., MEHRABYAN, A., SIMMONS, K., DUBLIN, C., BARLOW, P. & VINIK, A. I. 2005. Small fiber neuropathy is associated with the metabolic syndrome. Metabolic Syndrome and Related Disorders, 3,113-121.
RAFFAITIN, C., GIN, H., EMPANA, J.-P., HELMER, C., BERR, C., TZOURIO, C., PORTET, F., DARTIGUES, J.-F., ALPÉROVITCH, A. & BARBERGER-GATEAU, P. 2008. METABOLIC SYNDROME AND RISK FOR INCIDENT ALZHEIMER'S DISEASE OR VASCULAR DEMENTIA: THE THREE–CITY STUDY. Diabetes care.
RANASINHA, S., JOHAM, A., NORMAN, R., SHAW, J., ZOUNGAS, S., BOYLE, J., MORAN, L. & TEEDE, H. 2015. The association between Polycystic Ovary Syndrome (PCOS) and metabolic syndrome: a statistical modelling approach. Clinical endocrinology, 83, 879-887.
SATTAR, N., SCHERBAKOVA, O., FORD, I., O’REILLY, D. S. J., STANLEY, A., FORREST, E., MACFARLANE, P. W., PACKARD, C. J., COBBE, S. M. & SHEPHERD, J. 2004. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes, 53, 2855-2860.
SEYEDAN, A., ALSHAWSH, M. A., ALSHAGGA, M. A. & MOHAMED, Z. 2017. Antiobesity and lipid lowering effects of Orthosiphon stamineus in high-fat diet-induced obese mice. Planta medica, 83, 684-692.
SREE, N. V., SRI, P. U. & RAMARAO, N. 2015. Neuro-protective properties of orthosiphon staminus (benth) leaf methanolic fraction through antioxidant mechanisms on sh-sy5y cells: an in-vitro evaluation. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 6, 1115-1125.
SRIPLANG, K., ADISAKWATTANA, S., RUNGSIPIPAT, A. & YIBCHOK-ANUN, S. 2007. Effects of Orthosiphon stamineus aqueous extract on plasma glucose concentration and lipid profile in normal and streptozotocin-induced diabetic rats. Journal of Ethnopharmacology, 109, 510-514.
WEISS, R., BREMER, A. A. & LUSTIG, R. H. 2013. What is metabolic syndrome, and why are children getting it? Annals of the New York Academy of Sciences, 1281, 123-140.
WENS, I., DALGAS, U., STENAGER, E. & EIJNDE, B. O. 2013. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis–a systematic review. Multiple Sclerosis Journal, 19,1556-1564.
YIN, J., ZHANG, H. & YE, J. 2008. Traditional Chinese medicine in treatment of metabolic syndrome. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 8, 99-111.